<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01656629</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00050448</org_study_id>
    <nct_id>NCT01656629</nct_id>
  </id_info>
  <brief_title>Stem Cell Recruitment in Osteoporosis Therapy</brief_title>
  <official_title>Stem Cell Recruitment in Osteoporosis Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <brief_summary>
    <textblock>
      Osteoporosis is an important health problem in the rapidly-aging demographic. Fragility
      fractures are devastating consequences of osteoporosis. The most common treatment approach in
      osteoporosis is inhibition of bone resorption with drugs like alendronate (ALN). Parathyroid
      hormone (PTH) stimulates bone formation and is the only anabolic drug available. Dual therapy
      with ALN and PTH is not as effective as single-drug therapy in preventing fracture. Bone
      progenitor cells (MSCs) are recruited to sites of bone remodeling when a growth factor called
      Transforming Growth Factor Beta (TGF-β1) is released from bone. Different osteoporosis
      medicines may have differing effects on this process. The effects of ALN versus PTH on bone
      progenitor recruitment in humans are unknown. This is a randomized, clinical trial of ALN,
      PTH, and calcium and vitamin D in post-menopausal women with low bone mass. Women will be
      treated for 3 months with ALN or PTH or calcium and vitamin D. Data collected will include
      bone biopsies for histomorphometry and micro computed tomography (µCT), bone marrow aspirates
      for molecular studies, peripheral blood to detect circulating bone progenitor cells and dual
      X-ray absorptiometry. The investigators hypothesize that in humans, PTH will 1) increase bone
      progenitor number, 2) enhance recruitment of bone progenitor cells to bone resorption sites,
      and 3) increase bone progenitor number in peripheral circulation. Furthermore, the
      investigators hypothesize that ALN treatment will have the opposite effect. Understanding the
      differences in bone progenitor cell activity and recruitment during osteoporosis therapy will
      provide a mechanistic rationale for effective use of PTH and anti-resorptive drugs in
      osteoporosis treatment.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 2012</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Percent Change in Circulating Osteoprogenitor Cells as Assessed by Flow Cytometry in the Blood Before and After Treatment With Parathyroid Hormone (PTH) or Alendronate (ALN).</measure>
    <time_frame>up to 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in Bone Formation as Assessed by Bone Histomorphometry on Bone Biopsy Between Treatment Groups</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Osteogenic Potential of Bone Marrow as Measure by Colony Forming Unit Osteoblast (CFU-Ob) Assays Between Treatment Groups</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Low Bone Density</condition>
  <arm_group>
    <arm_group_label>teriparatide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>teriparatide 20 mcg sq for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alendronate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>70 mg po weekly for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>calcium and vitamin D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>calcium 630 mg vitamin D 500 units daily for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teriparatide</intervention_name>
    <description>20 mcg subq daily for 3 months</description>
    <arm_group_label>teriparatide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alendronate</intervention_name>
    <description>70 mg weekly for 3 months</description>
    <arm_group_label>Alendronate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>calcium and vitamin D</intervention_name>
    <arm_group_label>calcium and vitamin D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Post-menopausal women aged 50-80 years

          -  T score &lt; -2.5 at lumbar spine, total hip or femoral neck on dual x-ray absorptiometry
             (DXA) OR T score &lt; -1.5 with a personal or family history of fracture

        Exclusion Criteria:

          -  Previous use of bisphosphonates or Teriparatide; current estrogen therapy; any other
             osteoporosis therapy in the past 6 months

          -  Metabolic bone disease other than osteoporosis

          -  Body mass index (BMI) &lt; 18

          -  Weight &gt; 325 lbs

          -  Current smoking or current alcohol use that exceeds 3 units of alcohol daily

          -  Use of medications known to affect bone metabolism

          -  Renal disease, history of kidney stones or hypercalciuria

          -  Hypo- or hyperparathyroidism; hypo- or hypercalcemia

          -  Serum vitamin D level &lt; 20 ng/dL

          -  Refusal to adjust their dietary calcium to &lt;750mg (i.e. two servings per day of
             calcium rich food)

          -  History of bone marrow or organ transplant

          -  History of malignancy or radiation to the bone

          -  History of esophageal stricture, dysmotility or severe reflux disease

          -  Gastrointestinal malabsorption

          -  Use of digoxin

          -  Need for chronic anticoagulation therapy such as Coumadin, heparin or low molecular
             weight heparin or inability to discontinue anti-platelet medication

          -  Bleeding diathesis; hemoglobin ≤ 12.5 g/dL (American Red Cross cut-off to donate
             blood)

          -  International normalized ratio (INR) pro time &gt; 1.1 or activated partial
             thromboplastin time (APT) T ratio &gt; 1.2

          -  Platelets &lt; 150K/cu mm

          -  Cellulitis at site of iliac crest

          -  History of allergy to medications used in bone biopsy (demeclocycline, lidocaine)

          -  Inability to understand and provide informed consent.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suzanne Jan De Beur, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>August 1, 2012</study_first_submitted>
  <study_first_submitted_qc>August 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2012</study_first_posted>
  <results_first_submitted>July 16, 2019</results_first_submitted>
  <results_first_submitted_qc>July 16, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 8, 2019</results_first_posted>
  <last_update_submitted>July 16, 2019</last_update_submitted>
  <last_update_submitted_qc>July 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Alendronate</mesh_term>
    <mesh_term>Teriparatide</mesh_term>
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Teriparatide</title>
          <description>teriparatide 20 mcg sq for 3 months
Teriparatide: 20 mcg subq daily for 3 months</description>
        </group>
        <group group_id="P2">
          <title>Alendronate</title>
          <description>70 mg po weekly for 3 months
Alendronate: 70 mg weekly for 3 months</description>
        </group>
        <group group_id="P3">
          <title>Calcium and Vitamin D</title>
          <description>calcium 630 mg vitamin D 500 units daily for 3 months
calcium and vitamin D</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Teriparatide</title>
          <description>teriparatide 20 mcg sq for 3 months
Teriparatide: 20 mcg subq daily for 3 months</description>
        </group>
        <group group_id="B2">
          <title>Alendronate</title>
          <description>70 mg po weekly for 3 months
Alendronate: 70 mg weekly for 3 months</description>
        </group>
        <group group_id="B3">
          <title>Calcium and Vitamin D</title>
          <description>calcium 630 mg vitamin D 500 units daily for 3 months
calcium and vitamin D</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="16"/>
            <count group_id="B4" value="55"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>18 - 49 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50 - 80 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>81 - 100 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Percent Change in Circulating Osteoprogenitor Cells as Assessed by Flow Cytometry in the Blood Before and After Treatment With Parathyroid Hormone (PTH) or Alendronate (ALN).</title>
        <time_frame>up to 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Teriparatide</title>
            <description>teriparatide 20 mcg sq for 3 months
Teriparatide: 20 mcg subq daily for 3 months</description>
          </group>
          <group group_id="O2">
            <title>Alendronate</title>
            <description>70 mg po weekly for 3 months
Alendronate: 70 mg weekly for 3 months</description>
          </group>
          <group group_id="O3">
            <title>Calcium and Vitamin D</title>
            <description>calcium 630 mg vitamin D 500 units daily for 3 months
calcium and vitamin D</description>
          </group>
        </group_list>
        <measure>
          <title>The Percent Change in Circulating Osteoprogenitor Cells as Assessed by Flow Cytometry in the Blood Before and After Treatment With Parathyroid Hormone (PTH) or Alendronate (ALN).</title>
          <units>percent change in osteoprogenitor cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0000242" spread="0.0000283"/>
                    <measurement group_id="O2" value="0.0000104" spread="0.0000231"/>
                    <measurement group_id="O3" value="-0.0000068" spread="0.0000449"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in Bone Formation as Assessed by Bone Histomorphometry on Bone Biopsy Between Treatment Groups</title>
        <time_frame>3 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in Osteogenic Potential of Bone Marrow as Measure by Colony Forming Unit Osteoblast (CFU-Ob) Assays Between Treatment Groups</title>
        <time_frame>3 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Each participant was followed for 14 weeks for adverse events</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Teriparatide</title>
          <description>teriparatide 20 mcg sq for 3 months
Teriparatide: 20 mcg subq daily for 3 months</description>
        </group>
        <group group_id="E2">
          <title>Alendronate</title>
          <description>70 mg po weekly for 3 months
Alendronate: 70 mg weekly for 3 months</description>
        </group>
        <group group_id="E3">
          <title>Calcium and Vitamin D</title>
          <description>calcium 630 mg vitamin D 500 units daily for 3 months
calcium and vitamin D</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Gastrointestinal bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>There was a high level of variability and this data has not been validated.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Suzanne Jan De Beur</name_or_title>
      <organization>Johns Hopkins University</organization>
      <phone>410-550-0100</phone>
      <email>sjandebe@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

